Multidisciplinary Surgical Team Approach Improves OS in Ovarian Cancer
After implementing a multidisciplinary surgical approach, researchers found that use of the new approach, residual disease, and age were all independent predictors of overall and progression-free survival for patients with ovarian cancer.
Improved PFS in Advanced Ovarian Cancer With Senaparib vs Placebo
The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.
Triplet Maintenance Therapy Effective in Platinum-Sensitive Recurrent Ovarian Cancer
Results from the OPEB-01/APGOT-OV4 trial highlight the potential benefits of using olaparib, pembrolizumab, and bevacizumab as a triplet maintenance therapy for patients who have responded to chemotherapy after experiencing platinum-sensitive recurrence in ovarian cancer.
EMA Accepts Marketing Authorization Application for Mirvetuximab Soravtansine in FRα+, Platinum-Resistant Ovarian Cancer
The European Medicines Agency (EMA) has accepted a marketing authorization application seeking the approval of mirvetuximab soravtansine-gynx for the treatment of patients with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Cell-Free Liquid Biopsy Test for Ovarian Cancer Proves 91% Accurate
A study assessing an experimental cell-free DNA myelination liquid biopsy test was found to be 91% accurate at identifying early-stage epithelial ovarian cancer.
Association of Guideline-Concordant Care With Survival, Health Care Utilization, and Costs Among Older Women With Advanced Epithelial Ovarian Cancer
Non–guideline-concordant care for ovarian cancer was associated with higher all-cause and cancer-specific mortality, increased health care utilization, and increased Medicare expenditures, highlighting opportunities for improving cancer care in this vulnerable group.
Algorithm Reduces Unnecessary Oophorectomies in Pediatric Patients
The preoperative risk assessment algorithm can identify ovarian lesions with a strong likelihood of being non-cancerous and suitable for ovary-preserving surgery.
Dr Rebecca Brooks Gives Expert Advice, Resources for Patients With or at High Risk of Ovarian Cancer
More ovarian cancer drug approvals and treatments have become available since 2014 than in the preceding 60 years combined, emphasized Rebecca Brooks, MD, UC Davis Health.
FDA Grants Fast Track Designation to IDE161 for BRCA+, Platinum-Resistant Advanced Ovarian Cancer
The FDA has granted fast track designation to IDE161 for the treatment of adult patients with advanced or metastatic ovarian cancer harboring germline or somatic BRCA1/2 mutations who are platinum resistant and have received prior treatment with antiangiogenic and poly-ADP ribose polymerase, or PARP, inhibitor therapies.
Dr Rebecca Brooks Covers Ovarian Cancer Risk Factors, Preventive Measures
Family history is probably the biggest risk factor that patients need to know about, said Rebecca Brooks, MD, UC Davis Health.
"Forever" Chemical Levels Higher in Women With Ovarian, Breast, Other Cancers
Women with ovarian, breast, skin, and uterine cancers were found to have significantly higher levels of per- and polyfluoroalkyl substances (PFAS), phenols, and parabens in their bodies.
NACT Use Appears to Be Increasing in Less Common Epithelial Ovarian Cancers
Patients with low-grade serous ovarian cancer appear to have worse survival outcomes following treatment with neoadjuvant chemotherapy (NACT).
Innovative Combination Therapy Shows Promise for Late-Stage Ovarian Cancer
The treatment combined adoptive T-cell therapy with a personalized cancer vaccine and was found to be safe in a small cohort of 17 patients.
Atezolizumab Misses PFS End Point in Recurrent Epithelial Ovarian Cancer
Results from ATLANTE/ENGOT-ov29 show that atezolizumab did not significantly improve progression-free survival (PFS) compared with placebo plus bevacizumab for patients with platinum-sensitive ovarian cancer.
TTFields Plus Paclitaxel Misses OS End Point in Platinum-Resistant Ovarian Cancer
The phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial found the addition of tumor treating fields (TTFields) to paclitaxel did not provide a statistically significant improvement in overall survival (OS) vs paclitaxel alone for patients with platinum-resistant ovarian cancer, failing to meet its primary end point.
Study Highlights Factors Linked to ED Readmission Following Ovarian Carcinoma Surgery
Out of several factors, surgical complications were the only factor independently associated with emergency department (ED) readmission among patients who underwent surgery for ovarian carcinoma.
Ultrasonography-Based Ovarian Tumor Risk Models Show High Performance in US Cohort
A recent study found that ultrasonography-based risk models for differentiation between benign and malignant ovarian tumors performed well in a diagnostic study conducted in a US cohort.
Genomic Analysis Reveals Complex Alterations in HGSC
Investigators said analysis of multiple tissues from the same patients suggests tumor evolution in high-grade serous ovarian cancer (HGSC) was not through somatic mutations.
What We’re Reading: Drug Shortage Impacts Cancer Treatment; Consequences for Medicaid Money Misuse; Helping Children With Mental Illness
The platinum drugs most effective in treating ovarian cancer are in limited supply due to the drug shortage; the government proposes a plan to prevent hospitals from redistributing Medicaid money; physicians ask for help in treating the high number of children with mental illness coming to the emergency department.
Fallopian Tube Removal Not Linked to Ovarian Cancer Risk, Study Says
New research found that ovarian cancer risk is reduced by salpingectomy just as much as by tubal ligation, contradicting guidelines that suggest otherwise.
Exercise May Reduce Chemotherapy-Induced Peripheral Neuropathy Symptoms in Women With Ovarian Cancer
While there is currently no effective treatment for chemotherapy-induced peripheral neuropathy, one of the most common and severe adverse effects for patients who have undergone chemotherapy for ovarian cancer, a 6-month aerobic exercise intervention significantly improved symptoms.
64-Protein Signature May Predict Ovarian Cancer Response to Chemotherapy
Mount Sinai researchers discovered a 64-protein signature that may help predict whether patients with high-grade serous ovarian cancers will respond to chemotherapy.
Niraparib Maintenance Therapy Improves PFS by 55% in Advanced Ovarian Cancer
Results of the phase 3 PRIME study showed that treatment with niraparib with an individualized starting dose significantly extended progression-free survival (PFS) and reduced the risk of disease progression or death by 55% compared with placebo.
Case Study Details Rare Instance of Ovarian SCC Resulting From Endometriosis
Currently, there is no established standard of care treatment for ovarian squamous cell carcinoma (SCC).
Review Outlines Barriers to Guideline-Adherent Ovarian Cancer Care
Racial minority patients and low socioeconomic status patients tended to face the most barriers.
Tumor Differences Associated With Survival Outcomes in HGSC Ovarian Cancer
Investigators looked at both primary and metastatic tumors and found correlations between characteristics and patient outcomes.
In Ovarian Cancer, Postchemotherapy Immunological Modification Points to Later Relapse
Most cases of high-grade serous ovarian cancer are not diagnosed until the disease has reached an advanced stage.
NACT Use Is Growing in Rare Ovarian Cancers, but Certain Patients May Not Benefit
The findings come amidst growing use of the treatment approach.
Survey Details Concerns, Priorities of Women With Ovarian Cancer
In addition to a fear of cancer recurrence, patients said feeling isolated was also a challenge associated with having ovarian cancer.
Nurse Navigators Improve Rate, Timeliness of NGS in Ovarian Cancer
Rates of next-generation sequencing (NGS) more than doubled once a nurse navigation program was implemented.
2 Clarke Drive Cranbury, NJ 08512